公开(公告)号：WO2023031401A1

公开(公告)日：2023-03-09

申请号：PCT/EP2022/074453

申请日：2022-09-02

申请人： ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  SORBONNE UNIVERSITÉ

发明人： HANIN, Aurélie ,  NAVARRO, Vincent ,  CHAVEZ, Mario ,  DEMERET, Sophie

IPC分类号： G01N33/68 ,  G16H50/30

摘要： The invention relates to the field of patient's care and describes method and systems, for prediction of mortality, functional outcome and recovery after status epilepticus, based on machine classifiers and logistic regression functions, and using biological markers and variables easily obtainable in intensive care units.

公开(公告)号：WO2023012076A1

公开(公告)日：2023-02-09

申请号：PCT/EP2022/071463

申请日：2022-07-29

申请人： UNIVERSIDADE DE SANTIAGO DE COMPOSTELA ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITÉ D'ANGERS

发明人： MILBANK, Edward ,  LÓPEZ PÉREZ, Miguel Antonio ,  MARTINEZ MARTINEZ, María Del Carmen ,  ANDRIANTSITOHAINA, Ramaroson

IPC分类号： A61K38/45 ,  A61P3/04 ,  A61K35/15 ,  C12N15/52 ,  C12N5/0784

摘要： The present invention relates to a population of small extracellular vesicles (sEVs) for use in the treatment of obesity in a subject in need thereof, wherein the sEVs comprise at least one polynucleotide encoding a D168A dominant negative AMP-activated protein kinase alpha 1 (AMPKal-DN) mutant protein operably linked and under the control of a steroidogenic factor 1 (SF1) promoter, wherein the sEVs are engineered to transiently express in their outer membrane at least one fusion protein comprising the neurotrophic rabies virus (RVG) peptide fused to lysosome-associated membrane protein 2b. Said population is highly safe and effective, as the sEVs, when administered systematically, are capable of exerting their effect in the SF1 expressing neurons located in the ventromedial nucleus of the hypothalamus.

公开(公告)号：WO2021105926A2

公开(公告)日：2021-06-03

申请号：PCT/IB2020/061190

申请日：2020-11-26

申请人： CELLS FOR CELLS S.A. ,  CONSORCIO REGENERO, S.A. ,  UNIVERSIDAD DE LOS ANDES ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITÉ DE MONTPELLIER

发明人： LUZ CRAWFORD, Patricia ,  CONTRERAS LÓPEZ, Rafael ,  ELIZONDO VEGA, Roberto ,  DJOUAD, Farida

IPC分类号： C12N5/02 ,  C12N5/071 ,  C12N5/074 ,  C12N5/0789

摘要： Mesenchymal stem cells with enhanced therapeutic properties. The present invention refers to a method for obtaining mesenchymal stem cells (MSCs) with enhanced immunosuppression, chondroprotection and chondrodifferentiation properties, and enhanced capability to promote the proliferation of chondrocytes. The method comprises contacting the MSCs; culturing MSC in a induction media supplemented with 0.01 to 100 µg/ml of an ATP-synthase inhibitor; and removing the induction media to obtain MSC with enhanced activity. Moreover, the present invention also refers to the MSCs themselves and to their use for cell therapy purposes, preferably for treating autoimmune and/or osteoarticular diseases.

公开(公告)号：WO2020161045A1

公开(公告)日：2020-08-13

申请号：PCT/EP2020/052554

申请日：2020-02-03

申请人： ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  SORBONNE UNIVERSITÉ ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  VANDERBILT UNIVERSITY MEDICAL CENTER

发明人： SALEM, Joe-Elie ,  ALLENBACH, Yves ,  KERNEIS, Mathieu ,  MOSLEHI, Javid ,  JOHNSON, Douglas

IPC分类号： A61K45/00 ,  A61P35/00

摘要： The invention relates to the use of CTLA4 agonist for treating or preventing adverse events in patient treated with an immune checkpoint inhibitor.

公开(公告)号：WO2020099777A1

公开(公告)日：2020-05-22

申请号：PCT/FR2019/052689

申请日：2019-11-12

申请人： UNIVERSITE DE LORRAINE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE - INSERM

发明人： GRANDEMANGE, Stéphanie ,  MONARI, Antonio ,  GROS, Philippe ,  CARTRON, Pierre François

IPC分类号： A61K8/49 ,  A61Q19/00 ,  A61Q19/06 ,  A61K8/19 ,  A61K31/295 ,  A61P35/00 ,  A61P35/02

摘要： L'invention concerne l'utilisation non-thérapeutique, en tant qu'agent de déméthylation de l'ADN, d'au moins un composé organométallique comprenant un atome de fer lié à deux groupes terpyridines. L'invention porte également sur un composé organométallique comprenant un atome de fer lié à deux groupes terpyridines pour son utilisation comme médicament.

公开(公告)号：WO2020049133A1

公开(公告)日：2020-03-12

申请号：PCT/EP2019/073773

申请日：2019-09-05

申请人： NATIONAL UNIVERSITY OF SINGAPORE ,  INSTITUT PASTEUR DE LILLE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

发明人： ALONSO, Sylvie Claudette ,  LIM, Rui Fen, Annabelle ,  LOCHT, Camille ,  SOLANS, Luis

IPC分类号： A61K39/10 ,  A61P31/04

摘要： A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis- specific antibody profile and Thl7 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.

公开(公告)号：WO2020002430A1

公开(公告)日：2020-01-02

申请号：PCT/EP2019/067008

申请日：2019-06-26

申请人： CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITÉ DE MONTPELLIER (UM)

发明人： NOEL, Danièle ,  JORGENSEN, Christian ,  PERS, Yves-Marie ,  BONY-GARAYT, Claire ,  DE VOS, John

IPC分类号： C12N15/113 ,  C12N5/0775

摘要： The invention relates to the use of a composition comprising at least the miRNAs miR-155 and miR-27B, for stimulating, preferably in vitro, the immunosuppressive properties of mesenchymal stem cells, or MSCs.

公开(公告)号：WO2019077028A1

公开(公告)日：2019-04-25

申请号：PCT/EP2018/078522

申请日：2018-10-18

申请人： INSTITUT PASTEUR DE LILLE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

发明人： DEBRIE, Anne-Sophie ,  RAZE, Dominique ,  LOCHT, Camille

IPC分类号： A61K39/10 ,  A61K39/00

摘要： A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

公开(公告)号：WO2017216159A1

公开(公告)日：2017-12-21

申请号：PCT/EP2017/064409

申请日：2017-06-13

申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE PARIS SUD ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP) ,  HOPITAL MARIE LANNELONGUE

发明人： COHEN-KAMINSKY, Sylvia ,  HUMBERT, Marc ,  DUMAS, Sébastien ,  BRU-MERCIER, Gilles ,  MESSAOUDI, Samir ,  BRION, Jean-Daniel ,  ALAMI, Mouad ,  GALVANI, Gilles

IPC分类号： C07D451/02 ,  A61P11/00

摘要： The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

摘要翻译： 本发明涉及用作外周NMDA受体拮抗剂的式（I）化合物。

公开(公告)号：WO2016177664A1

公开(公告)日：2016-11-10

申请号：PCT/EP2016/059739

申请日：2016-05-02

申请人： GAMAMABS PHARMA ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER

发明人： CHARDÈS, Thierry ,  DUBREUIL, Olivier ,  PELEGRIN, André ,  LARBOURET, Christel ,  PROST, Jean-François ,  BARRET, Jean-Marc ,  DEGOVE, Stéphane

IPC分类号： C07K16/32 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/92

摘要： The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65 % of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.

摘要翻译： 本公开涉及具有人恒定区的神经调节蛋白非竞争性变构抗人HER3抗体; 并且由抗体的糖基化位点携带的少于65％的聚糖结构包含岩藻糖分子。 抗体的特征在于其可变序列。